Craig C. Hopkinson - 26 Feb 2026 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
26 Feb 2026
Net transactions value
-$93,696
Form type
4
Filing time
27 Feb 2026, 16:38:26 UTC
Previous filing
25 Feb 2026
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hopkinson Craig C. EVP R&D, Chief Medical Officer 900 WINTER ST., WALTHAM /s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson 27 Feb 2026 0001730048

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise +6,866 +7.7% 96,438 26 Feb 2026 Direct F1
transaction ALKS Ordinary Shares Tax liability $93,696 -3,049 -3.2% $30.73 93,389 26 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Restricted Stock Unit Award Options Exercise -6,866 -33% 13,732 26 Feb 2026 Ordinary Shares 6,866 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one ordinary share.
F2 Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/26/2025.